Our Natrix® chromatography membrane technology provides a new level of downstream productivity and versatility. The macroporous structure, combined with high functional group density, enables high load capacity and excellent impurity removal at ultra-fast flow rates. With great performance in a single-use and scalable format, our innovative Natrix® products improve process economics and facility utilization.
A high-capacity, high-throughput strong anion exchange membrane chromatography device designed for biomolecule purification, Natrix® Q chromatography membrane is a porous polyacrylamide hydrogel containing a high density of pendant quaternary ammonium (Q) binding groups directly polymerized within an inert, macroporous membrane scaffold. The interconnected pore structure and high functional group density enables fast flow rates with impressive throughput to extremely high loads while maintaining excellent impurity removal across a wide range of buffer conditions. Natrix® Q delivers improvements in productivity, flexibility, economic utility, and process robustness for any bioprocess design.
Protein A Affinity Chromatography Options
Bulk Resin, Membranes and Prepacked Columns
With a revolutionary three-dimensional macroporous hydrogel structure that provides a high density of binding sites and rapid mass transfer, Natrix® membranes deliver binding capacity that exceeds resin-based columns with fast flow rates.
With an innovative macroporous hydrogel structure that provides a high density of binding sites and rapid mass transfer, Natrix® Q anion exchange (AEX) chromatography membranes deliver higher binding capacities than resin-based columns at fast flow rates typical of traditional membrane adsorbers.
Natrix® chromatography membrane is a high capacity, high throughput strong anion exchange device designed to purify biomolecules.
Strong anion exchange (AEX) chromatography has become an industry standard in polishing steps for monoclonal antibody (MAb) purification.
Anion exchange chromatography is an important flowthrough polishing step for viral clearance of monoclonal antibodies (mAbs).
Respondents viewed intensified technologies as mostly single use at the clinical-stage and as mostly hybrid at the commercial scale.
To continue reading please sign in or create an account.
Don't Have An Account?